Fully biologically active when compared to standard. The ED50 as determined by its ability to agglutinate human red blood cells is less than 10μg/ml.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered solution in 1X PBS, pH7.4, 3mM DTT.
Endotoxin
Less than 0.1EU/μg of rHuGalectin-3 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Others
Background
Human Galectin-3 also named AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2, is belonging to the galectins family and it is encoded by a single gene, LGALS3, located on chromosome 14, locus q21–q22. It is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Galectin-3 is approximately 30kDa and, like all galectins, contains a carbohydrate-recognition-binding domain (CRD) of about 130 amino acids that enable the specific binding of β-galactosides. Given Galectin-3's broad biological functionality, it has been demonstrated to be involved in cancer, inflammation and fibrosis, heart disease, and stroke. Studies have also shown that the expression of galectin-3 is implicated in a variety of processes associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and Ventricular remodeling. Human Galectin-3 shares 79% amino acid sequence identity with rat and mouse Galectin-3, respectively.